Tamoxifen for breast cancer among hysterectomised women
2002; Elsevier BV; Volume: 359; Issue: 9312 Linguagem: Inglês
10.1016/s0140-6736(02)08159-x
ISSN1474-547X
AutoresUmberto Veronesi, Patrick Maisonneuve, Virgilio Sacchini, Nicole Rotmensz, Peter Boyle,
Tópico(s)Cancer Risks and Factors
ResumoSummary Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81·2 months, IQR 66·0–87·2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0·215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.
Referência(s)